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ABSTRACT
Background Familial hypercholesterolaemia (FH) is an
autosomal dominant disease of lipid metabolism, which
leads to early coronary heart disease. Mutations in LDLR,
APOB and PCSK9 can be detected in 80% of deﬁnite FH
(DFH) patients. This study aimed to identify novel
FH-causing genetic variants in patients with no
detectable mutation.
Methods and results Exomes of 125 unrelated DFH
patients were sequenced, as part of the UK10K project.
First, analysis of known FH genes identiﬁed 23 LDLR
and two APOB mutations, and patients with explained
causes of FH were excluded from further analysis.
Second, common and rare variants in genes associated
with low-density lipoprotein cholesterol (LDL-C) levels in
genome-wide association study (GWAS) meta-analysis
were examined. There was no clear rare variant
association in LDL-C GWAS hits; however, there were
29 patients with a high LDL-C SNP score suggestive of
polygenic hypercholesterolaemia. Finally, a gene-based
burden test for an excess of rare (frequency <0.005) or
novel variants in cases versus 1926 controls was
performed, with variants with an unlikely functional
effect (intronic, synonymous) ﬁltered out.
Conclusions No major novel locus for FH was
detected, with no gene having a functional variant in
more than three patients; however, an excess of novel
variants was found in 18 genes, of which the strongest
candidates included CH25H and INSIG2 (p<4.3×10−4
and p<3.7×10−3, respectively). This suggests that the
genetic cause of FH in these unexplained cases is likely
to be very heterogeneous, which complicates the
diagnostic and novel gene discovery process.
INTRODUCTION
Familial hypercholesterolaemia (FH (OMIM
#143890)) is a genetic disorder, inherited in an
autosomal dominant fashion, characterised by the
defective plasma clearance of low-density lipopro-
tein cholesterol (LDL-C) and caused by mutations
in three genes: LDLR, APOB and PCSK9.1 A reces-
sive form of FH due to mutations in LDLRAP1 is
also known.2 FH is estimated to affect one in 500
individuals3 and if untreated leads to premature
coronary heart disease (CHD).4 In the UK, the FH
Simon Broome criteria are used for the diagnosis,
which classify patients into possible FH, when
adults present with total cholesterol >7.5 mmol/L
or LDL-C >4.9 mmol/L, and family history of high
cholesterol or premature CHD, or the more severe
form—deﬁnite FH (DFH), when in addition to the
above, tendon xanthomas are present in the patient
or ﬁrst or second degree relative.5 The FH muta-
tion detection rate for DFH patients varies between
63% and 87%,6–8 suggesting that there are other
genetic causes, located outside of the currently
screened regions, which are yet to be identiﬁed.
The importance of identifying an FH-causing
variant, which has clinical utility in providing an
unequivocal diagnosis,9 has been emphasised by the
National Institute of Health and Care Excellence,
which in 2008 recommended cascade testing using
DNA information for ﬁnding the affected relatives
of a patient.10 The risk of early CHD can be signiﬁ-
cantly reduced by statin treatment,11 and genetic
information has been demonstrated to complement
the management of treated patients.12
Of FH patients where a mutation can be found,
∼93% occur in the LDLR gene.13 The APOB
variant (c.10580G>A, p.(Arg3527Gln)) accounts
for ∼5% of UK FH cases,7 8 14 whereas a
gain-of-function mutation in PCSK9 (c.1120G>T,
p.(Asp374Tyr)) can be found in roughly 1.7% of
FH patients.14 In the past few years, several loci
have been reported to cosegregate with FH in
family linkage studies; however, to date, this has
not led to the identiﬁcation of a speciﬁc causal
gene.15–17 It is likely that there are novel FH muta-
tions located in unknown genes inﬂuencing lipid
metabolism and that their discovery may contribute
to the identiﬁcation of novel treatment targets. In
order to ﬁnd novel causes of FH it was agreed that,
as part of the UK10K project (http://www.uk10k.
org/studies/rarediseases.html), the whole exomes of
125 unrelated DFH patients were sequenced at a
high depth. We expected that an FH-causing muta-
tion in a novel gene would be very rare accounting
for fewer FH cases than the gain-of-function muta-
tion in PCSK9 (1.7%), since a higher frequency
would have made likely its identiﬁcation in previ-
ous studies. We also suspected that a proportion of
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patients would have polygenic hypercholesterolaemia, due to
the combined impact of common LDL-C-raising SNPs.18
MATERIALS AND METHODS
Patients
A total of 125 unrelated patients, diagnosed as DFH using the
UK Simon Broome criteria on the basis of the presence or
family history of tendon xanthomas, were initially screened and
shown to be negative for mutations in known FH genes (LDLR,
APOB, PCSK9 and LDLRAP1). All consents and local review
board approvals were in accordance with the UK10K project
ethical framework. The initial mutation screening methods
varied and are summarised in online supplementary table S1.
Controls
The association with FH was tested against consented 1926
UK10K samples with no lipid abnormalities (listed in online
supplementary methods), sequenced in parallel, using the same
sequence capture and variant calling methods (http://www.
uk10k.org/studies/).
Exome sequencing and variant calling
The whole exome sequencing was performed and processed at
the Wellcome Trust Sanger Institute (Cambridge, UK) as part of
the UK10K project (see online supplementary methods). CNVs
were called using the ExomeDepth package for R (freely avail-
able at the Comprehensive R Archive Network).19
Filtering of the variants
Variants were ﬂagged as rare (frequency<0.5%) and novel (fre-
quency=0) according to their frequency in publicly available
databases including 1000 Genomes20 and National Heart, Lung,
and Blood Institute (NHLBI) Exome Sequencing Project
(ESP6500) (http://evs.gs.washington.edu/EVS/). In addition to
the frequency ﬁlters, a functional ﬂag was added, which priori-
tised variants that are most likely to affect a protein’s function,
that is, non-synonymous, stop gain, stop loss, frameshift dele-
tions and insertions, and splice site variants.
Burden test for association
Rare or novel variants were combined in a single gene manner
and counted in cases versus 1926 controls (ie, gene by gene).
A binomial test was used to assess the excess of functional rare
and novel variants in cases in comparison with the controls.
p Values lower than 4×10−3 were taken as evidence sufﬁcient to
be ﬂagged for follow-up.
Analysis of the variants
Variants within Tier 1 genes (LDLR, APOB, PCSK9, LDLRAP1)
were assessed on the basis of their frequency, and manually by
looking at their annotations in the UCL FH mutation data-
base.21 Sanger sequencing was used to conﬁrm all called muta-
tions. Samples with known FH mutations and therefore an
explained cause were removed from further analysis.
The Tier 2 list (see online supplementary table S2) consisted
of genes associated with LDL-C as a lead trait in the largest (at
the time) available Global Lipid Genetic Consortium (GLGC)
meta-analysis of genome-wide association studies (GWASs).22
Functional rare and novel variants in the Tier 2 genes were com-
pared by the burden test against non-FH controls, as one group
(counts in all genes combined) and by each single gene.
LDL-C gene score analysis
The possibility of polygenic hypercholesterolaemia in this
cohort was assessed using the LDL-C gene score analysis,
recently described.18 Most of the 12 LDL-raising GWAS SNPs
are located outside of the coding regions, and thus to obtain
these genotypes, methods as in the original publication were
used.18 Gene scores were calculated by summing the weights of
LDL-raising alleles provided by the GLGC (see online supple-
mentary table S3) and the APOE haplotype was scored as
follows: ε2ε2=−0.9, ε2ε3=−0.4, ε2ε4=−0.2, ε3/ε3=0,
ε3ε4=0.1 and ε4ε4=0.2.22 Gene scores of a randomly selected
subjects from the UK Whitehall II (WHII) study (n=3020) were
used as a healthy control comparison group.23 Individuals with
a gene score above 1.16, which was the top decile cut-off for
the WHII subjects, were considered to have polygenic hyper-
cholesterolaemia. The Welch two sample t test was used to test
for an overall difference between the groups.
RESULTS
We ﬁrst analysed variants in known FH genes (ﬁgure 1A) (for
gene coverage see online supplementary results). For LDLR, 10
individuals were carrying a missense mutation, ﬁve a nonsense
mutation, three had small deletions and two individuals had
intronic changes known to affect splicing (see online supplemen-
tary table S4). Analysis with ExomeDepth for CNVs identiﬁed
two large duplications and one deletion within the LDLR region
(see online supplementary ﬁgure S1). For APOB, two individuals
carried the known FH mutation, c.10580G>A (p.R3527Q),
and several novel and cases-unique APOB variants, distributed
across different gene exons, were identiﬁed (see online supple-
mentary table S5). These included a recently identiﬁed muta-
tion, p.R50W, which cosegregated with the disease.24 Because
APOB is highly polymorphic, the overall number of rare variants
was not signiﬁcantly different in comparison with controls.
PCSK9 had the lowest mean read depth (18×), with four exons
(1, 5, 9 and 10) covered less than 10× due to a high guanine
and/or cytosine (GC) content (see online supplementary ﬁgure
S2). There were no FH-causing variants identiﬁed in this gene.
There were no homozygous or compound heterozygous calls in
the LDLRAP1 gene in any of the samples. One patient was
found to be heterozygous for a previously identiﬁed frameshift
mutation (c.432_433insA (p.(Ala145LysfsX26))).25
LDL-C gene score analysis
Out of 109 FH samples (21 mutation positive, 88 mutation
negative) with sufﬁcient DNA for genotyping for all 12 SNPs,
31 had a gene score above the 1.16 cut-off (ﬁgure 1A), within
which two samples, in addition to the high gene score, had an
LDLR mutation, one in exon 11 (c.1690A>C (p.N564H))
found on the same allele as a 9bp deletion in exon
17 (c.2393_2401del9 (p.L799_V801del)), which has been
demonstrated as not fully-penetrant.26 The other was a deletion
of a consensus splice site at the 50 of exon 5, c.695-6_698del,
which has not been examined in vivo to conﬁrm its likely effect
on splicing.
The mean LDL-C gene score for the FH mutation negative
group was 1.08, which was signiﬁcantly higher than 0.90 for
the WHII study (p<2.2×10−16), and 0.96 for the FH mutation
positive group (p=0.006) (ﬁgure 1B) (for the distribution of
scores see online supplementary ﬁgure S3). The overall differ-
ence between the groups was signiﬁcant (analysis of variance
(ANOVA), p=1.33×10−12). Individuals with a gene score above
the top decile cut-off for the WHII subjects (>1.16), were
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considered to have polygenic hypercholesterolaemia and
excluded from further analysis as they were unlikely to carry a
single mutation of a strong effect.
GWAS LDL-C genes
We next examined any gene identiﬁed through GWAS as being
involved in determining levels of LDL-C in healthy individuals.22
A burden test on all functional rare and novel variants in any
gene singly or in all Tier 2 genes combined showed no obvious
candidate for a novel FH locus (see online supplementary table
S6). In addition, there were no loss-of-function variants (ie, pre-
mature stop codon formation, loss of a stop codon, frameshift
indels, CNVs) observed in these genes in any sample (n=125), or
in the 71 with no identiﬁed mutation and a low gene score.
There was no association of novel functional variants in any gene
located within the several loci identiﬁed by published family
linkage studies (see online supplementary table S7).
Whole exome analysis
In all, 25 samples carrying a mutation in Tier 1 genes and 29
with the LDL-C gene score above 1.16 were removed from
further analysis. To interrogate the whole exome, a burden test
was performed between 71 cases and 1926 controls. There were
4407 genes with one or more novel functional variant in cases.
In order to remove calls less likely to inﬂuence the FH pheno-
type and increase the power of the test, we limited further ana-
lysis only to genes where a maximum of four novel functional
variants were seen in the controls, based on the expected preva-
lence of FH of 1 in 500, and therefore any gene with >4 novel
functional variants in the controls were excluded (the original
gene list is shown in online supplementary table S8). Variants in
genes located on the X chromosome were removed from the
ﬁnal list (X chromosome genes shown in online supplementary
table S8). The next step involved a visual validation of the
quality of calls performed using the Human Genome 19 on the
Integrative Genomic Viewer (IGV).27 In order to avoid false
negatives, calls that were ﬁltered out due to inadequate quality
were reanalysed in genes showing excess of novel variants. An
additional loss-of-function variant, a premature stop codon at
the position c.244C>T (p.Q81*), was found in the CH25H
gene in an FH patient sample with a low LDL-C SNP score.
After adjusting for the false positives and false negatives,
Figure 1 Novel familial hypercholesterolaemia (FH) gene discovery pipeline. (A) To increase the chance of detecting true FH-causing variants with
a strong effect and reduce the noise, samples with a mutation in LDLR or APOB (apart from novel APOB variants of unknown effect) or those with a
high low-density lipoprotein cholesterol (LDL-C) gene score were removed from the analysis. The remaining variants were ﬁltered by their frequency
and functional effect and compared against controls. Genes with more than four novel functional variants in controls or genes located on the X
chromosome were ﬁltered out to enhance the power of the test. The remaining variants were manually assessed and false positive calls were
removed. (B) Comparison of the LDL-C SNPs score among the WHII control population (n=3020), FH mutation positive individuals (n=21) and FH
mutation negative individuals (n=83) in a standard boxplot (the minimum, lower quartile, median, upper quartile and maximum). The overall
difference between the groups was highly signiﬁcant (ANOVA, p<2.2×10−16). Dashed line indicates the top decile cut-off for the WHII cohort
(=1.16). A gene score was not attainable for 16 samples due to a poor DNA quality and insufﬁcient concentration, which resulted in incomplete
genotype data. (C) Schematic representation of the intronless CH25H gene and the localisation of novel variants identiﬁed in the FH cohort (in
boxes). CH25H encodes an enzyme, cholesterol 25-hydroxylase, known to be spanning the endoplasmic reticulum membrane, with two domains
(including the N-terminal) located outside of the membrane (in light grey), three 20 amino acid long transmembrane regions and two domains
positioned inside the membrane, which contain three His boxes, essential for the catalytic activity of the enzyme.30
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Table 1 Summary of genes and their variants which show an excess of novel functional variants in FH cases (n=71) in comparison with
controls (n=1926)
Gene Ch Number of variants in cases (n=71) Number of variants in controls (n=1926) p Value
CH25H 10 3 2 4.3×10−4
Cases ENST00000371852:exon1:c.G568A:p.V190I; exon1:c.A716C:p.H239P; exon1:c.C244T:p.Q82X
Controls ENST00000371852:exon1:c.T742G:p.C248G; exon1:c.C590A:p.P197Q
HSPB7 1 2 0 1.3×10−3
Cases 2X ENST00000311890:exon2:c.199+7G>A
Controls None
KLRC1 12 2 0 1.3×10−3
Cases ENST00000544822:exon5:c.G333C:p.Q111H; exon3:c.C178T:p.H60Y
Controls None
MOAP1 14 3 4 1.4×10−3
Cases ENST00000556883:exon2:c.C707T:p.A236V; exon2:c.G476C:p.C159S; exon2:c.A182G:p.N61S
Controls ENST00000556883:exon2:c.C655G:p.R219G; exon2:c.C627A:p.S209R; exon2:c.C264G:p.I88M; exon2:c.
A919G:p.I307V
RBM25 14 3 4 1.4×10−3
Cases ENST00000261973:exon6:c.A454T:p.I152F; exon2:c.T50C:p.L17P; exon11:c.C1364A:p.A455D
Controls ENST00000261973:exon7:c.C671T:p.A224V; exon11:c.A1273G:p.R425G; exon18:c.G2392A:p.V798I;
exon2:c.T7C:p.F3L
ANP32E 1 2 1 3.7×10−3
Cases ENST00000436748:exon3:c.G227C:p.S76T; ENST00000533654:exon4:c.A434G:p.K145R
Controls ENST00000436748:exon6:c.G629T:p.R210L
CABP5 19 2 1 3.7×10−3
Cases ENST00000293255:exon4:c.C281A:p.T94N; exon3:c.G201A:p.M67I
Controls ENST00000293255:exon3:c.A169C:p.M57L
CELA2B 1 2 1 3.7×10−3
Cases ENST00000375910:exon6:c.G576A:p.W192X; ENST00000422901:exon3:c.G271A:p.G91R
Controls ENST00000375910:exon7:c.T739C:p.Y247H
INSIG2 2 2 1 3.7×10−3
Cases ENST00000245787:exon2:c.T89C:p.I30T; exon2:c.C236T:p.T79M
Controls ENST00000245787:exon4:c.G376A:p.D126N
KCTD7 7 2 1 3.7×10−3
Cases ENST00000275532:exon4:c.G814A:p.V272M; exon4:c.C758T:p.S253L
Controls ENST00000275532:exon4:c.G506A:p.R169Q
MRO 18 2 1 3.7×10−3
Cases ENST00000436348:exon5:c.G578A:p.R193Q; exon5:c.G565A:p.V189I
Controls ENST00000436348:exon3:c.A223G:p.S75G
NR2E1 6 2 1 3.7×10−3
Cases ENST00000368983:exon1:c.G136A:p.G46S; exon5:c.A634G:p.M212V
Controls ENST00000368983:exon7:c.G1000A:p.V334I
PABPC1 8 2 1 3.7×10−3
Cases ENST00000318607:exon9:c.A1250C:p.Q417P;exon10:c.G1364A:p.R455H
Controls ENST00000523555:exon3:c.226+3A>G
PODXL 7 2 1 3.7×10−3
Cases ENST00000537928:exon3:c.G821A:p.R274K; exon5:c.A992G:p.H331R
Controls ENST00000537928:exon8:c.C1246G:p.Q416E
PUS3 11 2 1 3.7×10−3
Cases ENST00000530811:exon1:c.T74C:p.V25A; exon2:c.T824C:p.L275P
Controls ENST00000530811:exon4:c.945-8T>C
TXNDC15 5 2 1 3.7×10−3
Cases ENST00000511070:exon2:c.C130T:p.R44W; ENST00000507024:exon2:c.G91A:p.A31T
Controls ENST00000358387:exon2:c.G534C:p.E178D
WDR89 14 2 1 3.7×10−3
Cases ENST00000394942:exon2:c.T821C:p.L274S; exon2:c.A553G:p.M185V
Controls ENST00000394942:exon2:c.A860G:p.D287G
ZNF720 16 2 1 3.7×10−3
Cases ENST00000398696:exon2:c.T508G:p.L170V; exon2:c.A29G:p.H10R
Controls ENST00000399681:exon6:c.A893G:p.H298R
Ch, chromosome; FH, familial hypercholesterolaemia.
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CH25H remained the top gene (p<4.3×10−4) with three var-
iants in the cases and two in the controls (table 1). To examine
the prevalence of nonsense variants in CH25H in public data
sources, we analysed the NHLBI ESP database and found one
nonsense allele (c.638delT) in 6503 individuals (Minor Allele
Frequency (MAF)=0.00008), which was signiﬁcantly lower
than in the FH group (MAF=0.0003, p<1.5×10−3).
CH25H and INSIG2 variants
CH25H codes for cholesterol 25-hydroxylase, known to catalyse
the formation of the oxysterol—25-hydroxycholesterol (25-HC)
(9). The INSIG2 gene, which also exhibited an excess of novel
functional variants in the FH cohort in comparison with the
controls (p=3.7×10−3) (table 1), has been demonstrated to
regulate the activity of Sterol Regulatory Element-Binding
Protein (SREBPs), a family of major lipid metabolism transcrip-
tion factors, via direct biding of 25-HC.28 Thus, both genes,
CH25H and INSIG2, are involved in the same pathway of chol-
esterol metabolism. There were three heterozygous variants
found in CH25H, all conﬁrmed by Sanger sequencing (see
online supplementary ﬁgure S4), of which one leads to a forma-
tion of a premature stop codon at residue 81, predicted to have
a damaging effect on the protein; the second affects a well-
conserved residue across species, c.568G>A (p.V190I); and the
third, c.716A>C (p.H239P), alters one of the crucial residues
of the His Box 3 domain, known to play a crucial role, together
with His Boxes 1 and 2, in the catalytic activity of CH25H29
(ﬁgure 1C). Two novel functional variants were found in the
control cohort, both being non-synonymous (p.P197Q and p.
C248G). The p.P197Q is located in a conserved region of the
protein; however, it is predicted as tolerated/benign/neutral by
SIFT/PolyPhen/Mutation Taster. The p.C248G variant affects a
residue that is not conserved.30
Sanger sequencing also conﬁrmed two novel functional var-
iants in the INSIG2 gene called in the cases, both non-
synonymous changes (see online supplementary ﬁgure S5).
A mutation prediction report generated by Project HOPE31
highlighted that the c.89T>C (p.I30T) variant will cause an
empty space in the core of INSIG2 because of the size differ-
ences between the wild type Isoleucine and the smaller mutant
—Threonine. The other variant, c.236C>T (p.T79M), located
in the transmembrane domain of INSIG2, is predicted to have
an effect on the hydrophobic interactions within the core of the
protein or with the membrane lipids, because the mutant
Methionine is more hydrophobic than the wild type Threonine.
One rare missense variant was found in INSIG2 in the controls
(p.D126N), which was predicted as tolerated/probably dam-
aging/disease causing (by SIFT/PolyPhen/Mutation Taster).
DISCUSSION
In this study, we have identiﬁed 25 mutations in known FH
genes (23 in LDLR and two in APOB), which were missed by
the current screening protocol. Because the sequencing coverage
of the PCSK9 gene was lower than for LDLR and APOB, we
cannot rule out that there may have been undetected mutations
in this gene also. This ﬁnding conﬁrmed that LDLR locus is
highly heterogeneous and mutations within this gene account
for the majority of FH causes. The issue of genetic misdiagnosis
and the need for an update of current screening methods have
been previously discussed.32 In addition to the known FH muta-
tions, we identiﬁed six novel APOB variants, distributed across
different exons, in ﬁve patients, which included the recently
examined p.R50W variant.33 The pathogenicity of these var-
iants remains to be tested. Most of the current mutation
screening strategies for FH are focused on a selected region of
exon 26 of APOB, because of its established function;34
however, the whole exome sequencing enabled us to analyse the
entire coding sequence of the gene, by which we found novel
variants unique to the FH cohort.
Polygenic hypercholesterolaemia
The cumulative effect of common LDL-raising alleles in genes
identiﬁed by GWAS was shown to be the likely cause of high
LDL-C in a signiﬁcant proportion (27%) of the examined
patients. A gene score above the top decile for a healthy popula-
tion cut-off (1.16) was also observed in two patients with con-
siderably mild LDLR mutations, which demonstrates that
common polymorphisms can contribute to the presentation of
an individual carrying a mild effect FH mutation with LDL-C
levels above the diagnostic threshold.
GWAS LDL-C genes
Since common variants in the LDL-C-associated GWAS genes
were found to be important in the FH pathogenesis, we looked
for evidence that rare variants in these genes were causing FH.
Rare and novel functional variants in genes associated with
LDL-C levels in the GWAS meta-analysis were not signiﬁcantly
over-represented in the FH cohort, when compared with con-
trols. This suggests that rare variants that have a major effect
on function in these genes known to have common LDL-C
variants of modest effect are unlikely to be a common cause
of FH.
CH25H and INSIG2 variants
Genes CH25H and INSIG2 are the strongest candidates for novel
FH loci among the ﬁnal 18 genes, showing an excess of novel
functional variants, based on the available reports on functions of
the proteins for which they code. CH25H encodes 25-cholesterol
hydroxylase, which catalyses the formation of 25-HC from choles-
terol. The gene is located in close proximity to the LIPA gene in
which mutations were recently found in patients with autosomal
recessive FH phenotype.35 It has been demonstrated that both
cholesterol and 25-HC can regulate the function of SREBP, a tran-
scription factor known to regulate the expression of several key
players in the lipid metabolism.36 37 It is known that the regulation
of SREBP activity depends on binding of 25-HC to INSIG2,
encoded by the INSIG2 gene.28 The recently updated GLGC
GWAS study with >180 000 individuals has identiﬁed an associ-
ation at the genome-wide level of LDL-C with an INSIG2 gene
variant (rs10490626, MAF=0.08).38
The CH25H variants identiﬁed in this study have not been
observed in 1000 Genomes, 6500ESP and 69CG or the 1926
control exomes. We therefore decided to sequence the gene in
an additional cohort of 150 mutation negative FH patients with
a low gene score, but no additional amino acid changes were
identiﬁed.
A detailed literature search and gene ontology analysis of the
remaining 16 most signiﬁcant genes did not reveal any clear
association with lipid metabolism. We suspect that the majority
of these associations are false positives, and that increasing the
number of DFH cases would help to reduce the number of
chance signals. It is also possible that some of the top genes are
indeed affecting the plasma clearance of LDL-C; however, their
biology is yet to be understood.
There are a number of limitations to our study. An alternative
study design would be to use Next Generation Sequencing
(NGS) of relatives (or trios) from selected families with clear
autosomal dominant hypercholesterolaemia. The UK10K study
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only allowed for 125 subjects with FH to be included, and we
calculated that, if we selected 125 singleton no-mutation patients
with a clinical diagnosis of DFH, we would expect four to carry a
shared mutated locus leading to the defective plasma clearance of
LDL cholesterol. The power of the study is clearly dependent on
the number of singletons included, with the idea that any identi-
ﬁed candidate locus would be sequenced in the family members
of the affected proband. While a group of singletons may be gen-
etically heterogeneous, the use of the ‘burden’ analysis and not a
single-variant test means that heterogeneity should not reduce
power to detect a novel FH-causing gene. Another limitation is
that we did not have lipid proﬁle information for individuals in
the control comparison cohort, only their rare disease phenotype
status, which did not overlap with FH pathogenesis. The possibil-
ity that the control cohort includes FH-affected individuals was
considered. Assuming that the prevalence of FH is 1/500, we
would expect by chance to ﬁnd ∼4 individuals in this cohort car-
rying an FH-causing mutation. We have analysed variants in
LDLR, APOB and PCSK9 in the control cohort and identiﬁed
three LDLR and two APOB mutations as incidental ﬁndings,
which was similar to the expected FH frequency of one in 500.
We have also allowed for this prevalence in the control compari-
son cohort by using a frequency cut-off of four novel gene func-
tional variants in controls, in case any of the novel variants
identiﬁed in FH cases were also present in the controls. A ﬁnal
limitation is that it is possible that some of the identiﬁed variants
in the 18 genes in table 1 may be technical false positives, since
only for the CH25H and INSIG2 genes were all variants con-
ﬁrmed by Sanger Sequencing, However, to be as certain as pos-
sible using bioinformatics that the variants we observed are not
false positives, for all these variants we included a visual valid-
ation of the quality of calls performed using the Human Genome
19 on the IGV.27
In summary, in 125 DFH unrelated patients without an iden-
tiﬁed mutation by conventional screening methods, analyses
identiﬁed 25 disease-causing variants in already known FH loci,
as well as six previously unreported APOB variants in ﬁve
patients. LDL-C gene score analysis found that 31 (29 mutation
negative) patients had an SNP score in the top decile of the
general population and therefore had a deﬁnite polygenic aeti-
ology, and an additional ﬁve had a potential functional variant
in CH25H or INSIG2. This means that the explanation for the
FH phenotype is still lacking in 50% of the patients, suggesting
that some causal variants may have been missed at different
stages of the data processing or analysis. The variant calling
pipeline used for this study was carefully optimised for the
majority of the exome regions, though some calls in poorly
covered regions could be missed. There is a possibility that there
are genetic causes located outside of the protein coding region,
affecting protein expression, posttranscriptional stability or
altering gene splicing. Also, it is possible that the LDL-C gene
score cut-off of 1.16 for polygenic hypercholesterolaemia is too
stringent. Thus, using the 9th decile cut-off of 1.08, in which a
41% of WHII individuals had LDL-C above the 4.9 mmol/L
(mean LDL-C=4.68±1.05 mmol/L) FH diagnostic level, could
be more appropriate. By doing so, the phenotype would be
explained in an additional nine mutation-negative patients. A
polygenic explanation in additional subjects might also be
achieved if SNPs in recently identiﬁed LDL-C-raising loci38
were included in the score. Finally, because the burden test
results are dependent on the number of associated variants and
variants diluting the signal, it is possible that novel FH muta-
tions are located in a highly polymorphic gene, in which it is
difﬁcult to pick up the true mutation.
Thus, overall, no major novel locus for FH was detected,
with no gene having a functional variant in more than three
patients. This suggests that the genetic cause of FH in these
unexplained cases is likely to be very heterogeneous, which
complicates the novel gene discovery and diagnostic process.
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